Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
based decrease » caused decreased (Expand Search), marked decrease (Expand Search), based defense (Expand Search)
teer decrease » mean decrease (Expand Search)
Showing 21 - 40 results of 6,535 for search '(( significantly ((teer decrease) OR (greater decrease)) ) OR ( significant based decrease ))', query time: 0.59s Refine Results
  1. 21
    Sobel test for the significance of the mediation effect.

    Sobel test for the significance of the mediation effect. by Getachew Magnar Kitila (19935139)

    Published 2024
    Save to List
    Saved in:
  2. 22
    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.

    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

    Published 2024
    “…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. (<b>B)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on day 22. …”
    Save to List
    Saved in:
  3. 23
    Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells.

    Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

    Published 2024
    Save to List
    Saved in:
  4. 24
    Change in Watt’s Connectedness Scale, Subscales by Treatment Group.

    Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 25
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 26
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 27
    Study-related adverse events.

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 28
    Study flow chart.

    Study flow chart. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 29
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 30
    Study CONSORT diagram.

    Study CONSORT diagram. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 31
    Change in Demoralization Scale (DSII) by Treatment Group.

    Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 32
    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group.

    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 33
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 34
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 35
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 36
    Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period.

    Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed... by Jelena Filimonovic (22305307)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 37
    Frequency distribution of SOLEC at baseline and follow-ups in WAD grade 2 and WAD grade 3.

    Frequency distribution of SOLEC at baseline and follow-ups in WAD grade 2 and WAD grade 3. by Anneli Peolsson (7867601)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 38
    The CONSORT flow diagram.

    The CONSORT flow diagram. by Anneli Peolsson (7867601)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 39
    Linear mixed model results, fixed effects for time points, group, time points x group and univariate effects in the two groups WAD grades 2 and 3.

    Linear mixed model results, fixed effects for time points, group, time points x group and univariate effects in the two groups WAD grades 2 and 3. by Anneli Peolsson (7867601)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 40
    Baseline descriptive characteristics of trial participants (n = 140) with and without dizziness.

    Baseline descriptive characteristics of trial participants (n = 140) with and without dizziness. by Anneli Peolsson (7867601)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: